keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
Published 5 years ago • 469 plays • Length 3:10Download video MP4
Download video MP3
Similar videos
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
6:58
keynote-426 study
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:04
tian zhang, md, elaborates on the outcomes of keynote 426 presented at gu 2019
-
1:46
researcher comment: updated keynote-426 data | elizabeth plimack
-
1:44
renal cancer highlights from 2019 gu: keynote-426
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
4:40
pembrolizumab plus axitinib in the second-line and beyond for mrcc
-
2:16
updated results from keynote-426 for metastatic kidney cancer
-
7:04
sunitinib 4/2 vs 2/1 schedule for patients with mrcc
-
2:12
results of a trial comparing cabozantinib and sunitinib in mrcc
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)